S
SCHOLAR ROCK HOLDING CORP
NASDAQ: SRRK (Scholar Rock Holding Corporatio)
最近更新时间: 21小时之前32.91
0.15 (0.46%)
| 前收盘价格 | 32.76 |
| 收盘价格 | 33.00 |
| 成交量 | 1,307,834 |
| 平均成交量 (3个月) | 1,172,303 |
| 市值 | 3,121,849,088 |
| 价格/销量 (P/S) | 13.14 |
| 股市价格/股市净资产 (P/B) | 8.34 |
| 52周波幅 | |
| 利润日期 | 5 May 2025 - 9 May 2025 |
| 稀释每股收益 (EPS TTM) | -2.47 |
| 总债务/股东权益 (D/E MRQ) | 17.67% |
| 流动比率 (MRQ) | 9.61 |
| 营业现金流 (OCF TTM) | -200.95 M |
| 杠杆自由现金流 (LFCF TTM) | -111.55 M |
| 资产报酬率 (ROA TTM) | -40.09% |
| 股东权益报酬率 (ROE TTM) | -82.95% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Scholar Rock Holding Corporatio | 混合的 | 看涨 |
AIStockmoo 评分
2.0
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 2.00 |
|
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.87% |
| 机构持股比例 | 116.34% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Siren, L.L.C. | 31 Dec 2024 | 9,250,005 |
| Samsara Biocapital, Llc | 31 Dec 2024 | 5,612,896 |
| Redmile Group, Llc | 31 Dec 2024 | 4,549,881 |
| Polar Capital Holdings Plc | 31 Dec 2024 | 2,708,371 |
| Eventide Asset Management, Llc | 31 Dec 2024 | 2,659,240 |
| Fairmount Funds Management Llc | 31 Dec 2024 | 1,962,953 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合